Objectives: To investigate the patterns and frequency of multiple risk behaviours (alcohol, drugs, smoking, higher risk sexual activity) among men who have sex with men (MSM) living with HIV. Methods: Cross sectional study. Results: 147 out of 819 HIV-positive MSM exhibited a high-risk phenotype (defined as >3 of smoking, excess alcohol, sexually transmitted infection and recent recreational drug use). This phenotype was associated with younger age, depressive symptoms and <90% adherence in multivariable logistic regression. Conclusion: In a cohort of MSM, a small, but significant proportion exhibited multiple concurrent risk behaviours.
Bibliographical noteFunding Information:
Conflicts of interest: AW has received honoraria or research grants from, or has been a consultant or investigator in clinical trials sponsored by, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Pfizer and ViiV Healthcare. JHV has received funding from Janssen-Cilag, Gilead Sciences and AbbVie for travel or sponsorship to attend scientific conferences, and honoraria from Merck and Janssen-Cilag for speakers’ bureaus. PWGM has received funding for serving on advisory boards and speaker panels and for preparation of educational materials and/or research grants to his institution from Gilead Sciences, ViiV Healthcare, BMS, MSD, AbbVie and Janssen-Cilag. FAP has received funding from Gilead Sciences, ViiV Healthcare, MSD and Janssen for membership of advisory boards and speaker panels and/or for the preparation of educational materials. AP reports grants from Gilead Sciences and personal fees from Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and ViiV Healthcare and is a panel member on EACS and BHIVA ARV Guidelines. MB has received speaking fees from Gilead, MSD/Merck and Janssen, advisory fees from ViiV, Gilead and MSD/Merck, honoraria from Gilead for speakers’ bureaus and a travel grant from Gilead and has been the principal investigator in clinical trials sponsored by Gilead, ViiV, Mylan, Janssen and Bristol-Myers Squibb. JA receives grants, personal fees and nonfinancial support from Gilead Sciences, MSD, Janssen, BMS and ViiV. CAS has received funding from Gilead Sciences, ViiV Healthcare and Janssen-Cilag for the membership of data safety and monitoring boards, advisory boards and speaker panels and for the preparation of educational materials. ERMP, EB, MS, IW, MJ and LB have nothing to declare.
Financial disclosure: POPPY funders: the POPPY study is funded from investigator-initiated grants from BMS, Gilead Sciences, Janssen, MSD and ViiV Healthcare. The research is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London and by an NIHR Senior Investigator Award to CAS (NF-SI-0514-10075). This work was undertaken when ERMP was funded by an NIHR Academic Clinical Fellowship. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
© 2018 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association
- mental health
- recreational drugs
- risk behaviours